Advanced triple quadrupole technology for improved performance and ease of use.
In all mass spectrometry applications, increased resolution, mass accuracy, and speed are sought. While the necessary resolution and sensitivity can be achieved by pushing an older instrument to its limits, the consequences of doing so are often more challenging method development and sample analysis and more frequent maintenance resulting from larger injection volumes, explains Patrick Bennett, marketing director for pharmaceuticals and biopharmaceuticals at Thermo Fisher Scientific (TFS).
Two new instruments from TFS address the need for increased sensitivity for small-molecule analysis. “The TSQ Endura triple-stage quadrupole mass spectrometer has a new ion source design and interface and an ion beam blocker that prevents neutral ions from contaminating components, thus improving robustness and dramatically increasing uptime, making the system ideal for workhorse applications requiring trace-level quantitation,” Bennett observes.
The TSQ Quantiva triple-stage quadrupole mass spectrometer has the same new source and simplified maintenance design as the TSQ Endura, plus active ion management (AIM) to optimize ion creation and transmission from the source to the detector, which provides sensitivity to the attogram level. According to Bennett, the increased scanning speed of the new design also makes it possible to screen several hundreds of compounds in a single analysis.
TFS also made the user interface for each system simple with click-and-drag operations, and included new software with templates for rapid method development and data acquisition, programs designed to assist molecule identification, and mass spectral databases for the identification and structural elucidation of unknowns. “Our goal was not only to develop highly sophisticated systems that provide the resolution, speed, and mass accuracy needed for various pharmaceutical industry analyses, but also to make them easy to use by both those with extensive training and those that are new to mass spectrometry,” states Bennett. increasing numbers of complex and innovative products and suppliers and discuss ways the pharmaceutical industry can collaborate to assure the delivery of high-quality medicines in an ever-increasing complex and global marketplace.
WMFTS’ BioPure to Showcase Single-Use Bioclamp with Refined Manufacturing at INTERPHEX 2025
April 1st 2025With advanced manufacturing, BioPure’s BioClamp connector is manufactured to be 13% lighter than the previous model, resulting in a 26% reduction in carbon dioxide emissions across the full lifecycle of the product.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.